Navigation Links
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
Date:9/21/2008

t http://www.mslifelines.com for prescribing information.

* The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.

About Merck Serono and multiple sclerosis

Merck Serono is a leader in multiple sclerosis (MS) with Rebif(R) (interferon beta-1a), a disease-modifying drug used to treat relapsing forms of MS, which is registered in more than 80 countries worldwide. Full prescribing information for Rebif(R) can be obtained by contacting the Company or visiting its website. Additional therapeutic options are currently under development at Merck Serono, including oral cladribine, currently in Phase III and potentially the first oral therapy for MS, as well as several products in early stage development. Merck Serono also is taking a leading role in developing an understanding of the role of genetics in MS.

About multiple sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the nervous system and is the most common, non-traumatic, disabling, neurological disease in young adults. The World Health Organization estimates that up to 2.5 million people suffer from MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

About Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.

Merck Serono has leading brands serving patients with cancer (Erbitux(R
'/>"/>

SOURCE Merck Serono
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Brooke Franchise Corporation Announces Selected July Results
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
6. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
7. Martek Announces Third Quarter 2007 Financial Results
8. MDS Reports Third Quarter 2007 Results
9. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... unprecedented medical, economic burdens, study pr...ws) -- The number of people with diabetes in the U...5 years, a new study predicts. , That would bri...with the disease, up from 23.7 million today. , ,...th diabetes will triple, the study also warns, ris...
(Date:11/27/2009)... Voyant Health™ announced today that Spec...its TraumaCad Enterprise orthopedic templating sol... , (PRWEB) November 27, 20...ectrum Health (Grand Rapids, Michigan) has license...olution and its TraumaCad Extend workflow solution...
(Date:11/27/2009)... Specialist manufacturers who use medical load ...llions of dollars by bringing in technology partne...numbers of pro-active medical manufacturers are ca...stage of their projects, ensuring that progress wi... or potentially outdated technology. , ...
(Date:11/26/2009)...Nov. 27 With cold and flu season u...od practices to control the spread of infections a...ot only to keep ourselves healthy, but to avoid tr...erty, RN, MS, CIC (certified in infection-control)...ational health at Hospital for Special Surgery (HS...
(Date:11/26/2009)..., the number of Americans living with diabetes wil...009 to 44.1 million in 2034. Over the same period,...rom $113 billion to $336 billion, even with no inc...sed at the University of Chicago report in the Dec...those with diabetes covered by Medicare will rise ...
Breaking Medicine News(10 mins):Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
...world-leading publisher of scientific, technical a...leased to announce the launch of a new journal, en...ease dynamics ( http://www.elsevier.com/locate/epi...ynamics of infectious agents, and dynamics at the ...
...ly anticipated Food and Drug Administration (FDA) ...poses in 2006, saline-filled implants remain the m..., according to a study published in the March/Apr...dministration (FDA) approval of silicone gel impla...
...l partner and customer pilots in Europe and Asia d... RFID Journal Live - Booth #333- With deployments...in multiple retail, manufacturing and healthcare i...TLS), today announced general worldwide availabili...
...al Infertility Awareness Week(R), April 25 - May 2... 27 Ferring Pharmaceuticals, which offers the bro...., has partnered with leading patient advocate org...(NIAW), April 25-May 2. The program was developed...
... close monitoring, researchers say, , , MO...ffective, treating prostate cancer with the testos...ation therapy may raise men,s risk for developing ...noted. But the study shines fresh light on the que...
... Senior Living, Inc. (OTC Bulletin Board: TCSR), w... living facilities, today announced the expansion ...e Perspectives, a nationally syndicated Christian...dience, and we are excited to continue our relatio...
Other Medicine News:Health News:Elsevier launches Epidemics -- the journal on infectious disease dynamics 2Health News:Breast Augmentation: Survey Highlights Recent Trends In Today's Most Popular Cosmetic Surgery Procedure 2Health News:Breast Augmentation: Survey Highlights Recent Trends In Today's Most Popular Cosmetic Surgery Procedure 3Health News:Breast Augmentation: Survey Highlights Recent Trends In Today's Most Popular Cosmetic Surgery Procedure 4Health News:Time Domain Goes Global, Announces Worldwide Availability of its PLUS(TM) Ultra Wideband Real-Time Location System Sensor Platform 2Health News:Time Domain Goes Global, Announces Worldwide Availability of its PLUS(TM) Ultra Wideband Real-Time Location System Sensor Platform 3Health News:Time Domain Goes Global, Announces Worldwide Availability of its PLUS(TM) Ultra Wideband Real-Time Location System Sensor Platform 4Health News:Ferring Pharmaceuticals and RESOLVE: The National Infertility Association Join Together to Launch Nurse Liaison Program 2Health News:Ferring Pharmaceuticals and RESOLVE: The National Infertility Association Join Together to Launch Nurse Liaison Program 3Health News:Heart, Bone Problems May Follow Prostate Cancer Treatment 2Health News:Heart, Bone Problems May Follow Prostate Cancer Treatment 3Health News:National Radio Program to Expand Awareness of TrinityCare's Unique Approach to Senior Adult Care 2Health News:National Radio Program to Expand Awareness of TrinityCare's Unique Approach to Senior Adult Care 3
(Date:11/25/2009)..., , NEW YORK, Nov. 25 /PRNewswire/ -...earch report is available in its catalogue: ,, ...ive ,, http://www.reportlinker.com/p0164330/...e.html ,, Rising incidence of breast cancer in... principal factor influencing growth in the mammog...
(Date:11/25/2009)..., , EAST BRUNSWICK, N.J., Nov. 25 /PRNe...manufacturer of direct digital Radiography ( ddR )... been acquired by a private Swiss Investor with a ...imaging brand. The acquisition included all assets...nd inventory. After 25 years of success and growth...
(Date:11/25/2009)..., , SAN DIEGO, Nov. 25 /PRNewswire...medical device company focused on developing produ...or the spine, announced today that it will host a ...:30 p.m. ET / 2:30 p.m. PT. The conference call w...ent for the Company,s products and will include co...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8Swissray International Announces New Ownership 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4ThermoGenesis Announces Expanded Collaboration With Celling Technologies 13437 1ThermoGenesis Announces Expanded Collaboration With Celling Technologies 13437 2ThermoGenesis Announces Expanded Collaboration With Celling Technologies 13437 3ThermoGenesis Announces Expanded Collaboration With Celling Technologies 13437 4Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10 2009 13433 1Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10 2009 13433 2Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 53902 1Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 53902 2Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 53902 3
Tying Forceps - Pierse
Sheets-McPherson Angled Tying Forceps
Osher Ultra Fine Tying Forceps
O'Gawa Angled Tying Forceps
Medicine Products: